Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that it was informed yesterday that Fairford Capital Ltd, of which Michael Bradfield,
Michael Sinclair, CEO of Advanced Oncotherapy LON:AVO, said: “2015 has been a year of significant progress for the Company. We have delivered on all of the milestones that were promised
Nicolas Serandour, COO and CFO of Advanced Oncotherapy LON:AVO, commented: “We are delighted to have secured this financing partnership with Metric Capital. Vendor financing has become standard practice in the
Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has talked to DirectorsTalk about a number of shareholders that have raised concerns that a
Our key feature this month is a review of the UK/EU Electricity sector by Nigel Hawkins who has recently joined Hardman to cover the utilities and renewable energy market. Nigel
Michael Sinclair, CEO of Advanced Oncotherapy, commented: “The team at Advanced Oncotherapy have been working hard in progressing the construction of our first LIGHT system and I am delighted that
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that Michel Baelen has joined the Company as Head of Regulatory Affairs and
Beaufort Securities view on Advanced Oncotherapy: Yesterday’s agreement with Thales tells investors two things: (i) That the signing of an agreement with such a highly prestigious global operator, that generally
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that it has entered into an industrialisation agreement with Thales, for its proprietary LIGHT
Advanced Oncotherapy Plc (LON:AVO) Focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN facility in Switzerland.
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
